SFX by Ex Libris Inc.

Title:	Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system
Source:	Methods [1046-2023] Ruitenberg, Marc yr:2002

Basic

Full text

Full text available via EZB-NALI5-00465 Elsevier Archive NL

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Peel, A L L. "Adeno-associated virus vectors: activity and applications in the CNS." Journal of Neuroscience Methods 98.2 (2000): 95-104.
description	2.	Gao, Guangping P. "New recombinant serotypes of AAV vectors." Current gene therapy 5.3 (2005): 285-297.
description	3.	Janson, C G G. "Viral-based gene transfer to the mammalian CNS for functional genomic studies." Trends in neurosciences 24.12 (2002): 706-712.
description	4.	Flotte, Peter W S. "Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors." Molecular therapy 6.3 (2002): 394-9.
description	5.	Seth P, P. "Vector-mediated cancer gene therapy: an overview." Cancer biology & therapy 4.5: 512-7.
description	6.	Xiao, X. "Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart." Nature biotechnology 23.3 (2005): 321-8.
description	7.	Franich, Nicholas R. "AAV Vectorâmediated RNAi of Mutant Huntingtin Expression Is Neuroprotective in a Novel Genetic Rat Model of Huntington's Disease." Molecular therapy 16.5 (2008): 947-956.
description	8.	Kaplitt, M G. "Viral Vectors for Gene Delivery and Expression in the CNS." Methods 10.3 (1996): 343-350.
description	9.	Engelhardt, S F. "Rate limiting steps of AAV transduction and implications for human gene therapy." Current gene therapy 1.2 (2001): 137-47.
description	10.	Dormond, E. "From the first to the third generation adenoviral vector: what parameters are governing the production yield?" Biotechnology advances 27.2 (2009): 133-44.
description	11.	Davidson, R M L. "Recombinant Adeno-Associated Virus Type 2, 4, and 5 Vectors: Transduction of Variant Cell Types and Regions in the Mammalian Central Nervous System." Proceedings of the National Academy of Sciences of the United States of America 97.7 (2000): 3428-32.
description	12.	Yew, N S S. "Optimization of plasmid vectors for high-level expression in lung epithelial cells." Human gene therapy 8.5 (1997): 575-84.
description	13.	Rivera, A. "Pyruvate dehydrogenase deficiency: identification of a novel mutation in the PDHA1 gene which responds to amino acid supplementation." European journal of pediatrics 168.1 (2008): 17-22.
description	14.	Makrides, SC. "Strategies for achieving high-level expression of genes in Escherichia coli." Microbiology and molecular biology reviews 60.3 (1996): 512-538.
description	15.	Cho, Yong o. "Polycation gene delivery systems: Escape from endosomes to cytosol." Journal of Pharmacy and Pharmacology 55.6 (2003): 721-34.
description	16.	Daly, Thomas M M. "Overview of adeno-associated viral vectors." Methods in molecular biology 246 (2004): 157-65.
description	17.	El-Aneed, A. "An overview of current delivery systems in cancer gene therapy." Journal of controlled release 94.1 (2003): 1-14.
description	18.	Shaughnessy, L. "Novel approaches to models of Alzheimer's disease pathology for drug screening and development." Journal of molecular neuroscience 24.1: 23-32.
description	19.	Meghrous, J. "Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor." Biotechnology progress 21.1 (2005): 154-160.
description	20.	Samulski, R Jude W. "Production and characterization of adeno-associated viral vectors." Nature protocols 1.3 (2006): 1412-28.